Tariffs
← 실적 발표
01
02
03
04 05 06
톤
A1 A2 A3 A4
KVUE
FY2025 Q1
둔화
Kenvue Inc. 실적 발표
Buzzberg 분석
Tariffs to cause $150M gross 2025 cost impact
Kenvue's Q1 results were in line with its muted expectations, but FY25 EPS and margin guidance were lowered due to tariff assumptions. Management highlighted some strong consumption/share gains in the US offset by China destocking and category softness, updating its outlook to reflect a highly uncertain environment. Q1 organic sales declined 0.2% year-over-year, consistent with guidance, but adjusted EPS of $0.24 was reported with a $0.02 currency headwind.
Buzzberg 분석 Tariffs to cause $150M gross 2025 cost impact Kenvue's Q1 results were in line with its muted expectations, but FY25 EPS and margin guidance were lowered due to tariff assumptions. Management highlighted some strong consumption/share gains in the US offset by China destocking and category softness, updating its outlook to reflect a highly uncertain environment. Q1 organic sales declined 0.2% year-over-year, consistent with guidance, but adjusted EPS of $0.24 was reported with a $0.02 currency headwind. 전체 분석 보기분석 접기
Kenvue's Q1 results were in line with its muted expectations, but FY25 EPS and margin guidance were lowered due to tariff assumptions. Management highlighted some strong consumption/share gains in the US offset by China destocking and category softness, updating its outlook to reflect a highly uncertain environment. Q1 organic sales declined 0.2% year-over-year, consistent with guidance, but adjusted EPS of $0.24 was reported with a $0.02 currency headwind.
- FY25 adjusted EPS and operating margin guidance were both lowered to reflect the estimated $150M gross tariff impact, with EPS now expected to be flat year-over-year.
- FY25 net sales growth from FX improved to 1-3% from 0-2% due to a weaker dollar; organic sales growth outlook maintained at -4% to 0%.
- Consumption outpaced organic sales growth in all segments in Q1, signaling share gains and successful US price/trade initiatives, particularly in self-care and skin health.
매출$3.741B보고값
주당순이익(EPS)$0.24보고값
매출총이익률57.95%보고값
영업이익률14.92%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Guidance
Q1 organic sales declined 0.2% as planned
Guidance
Company maintains 2025 organic sales growth outlook of 2-4%
핵심 내용 3개 더 보기
Leadership
CFO transition: Amit Banati joins May 12
Demand
China destocking headwind expected to end by Q2
Margins
Adjusted operating margin now expected to contract slightly for full year
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $3.741B | 보고값 |
| 주당순이익(EPS) | $0.24 | 보고값 |
| 매출총이익률 | 57.95% | 보고값 |
| 영업이익률 | 14.92% | 보고값 |
| 잉여현금흐름 | $0.249B | 보고값 |
| 자본지출 | $0.179B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 주당순이익(EPS) | FY2025 | $0.00 | $0.00 | 하향 |
| 영업이익률 | FY2025 | 0% | 0% | 하향 |
| 매출 | FY2025 | $0B | $0B | 유지 |
AI, 자본지출 및 수요 분석
경영진 분석
Cautious
Management acknowledged a dynamic and fluid macro environment, including tariffs, category deceleration, and seasonal shifts, while expressing confidence in their strategic plan and back-half acceleration.
아래에 언급된 기업 8개 모두 표시
기업발표 이후 수익률
파트너
파트너
Thibaut Mongone
Kenvue's full exit from J&J's transition services agreements marks its independence, potentially freeing it from legacy overhead but also ending a revenue stream for J&J.
근거
“In April, we reached a major operational milestone, completing our transition services agreement program, finalizing the exit of more than 2,300 TSAs as per plan and without any disruption to our business.”
공급망
공급망
Thibaut Mongone
The incoming CFO's history at Kellanova is mentioned in a Q&A; it's a reference to his background, not a statement about either company's current trajectory.
근거
“he's probably most closely associated today with seeing Kellogg through the Kellenova WK Kellogg separation and the subsequent sale of Kellenova to Mars.”
공급망
Thibaut Mongone
April US retail orders tightened, which combined with a delayed allergy/sun season, may shift volumes into later quarters. — This signals the consumer staples sector overall faces a near-term demand pull-forward/deferral dynamic, potentially pressuring H1 sales for peers while setting up a potentially stronger H2.
근거
“from a macro point of view, we have seen some retailers tightening order management in April in the US. So these two factors may shift volumes from one quarter to the next.”
공급망
Thibaut Mongone
Consumption outpaced organic sales growth across all segments in Q1, driven by US price/trade investment, indicating Kenvue is gaining share and household penetration in the US despite retailer destocking. — This suggests the US price/trade investments are driving market share gains for Kenvue, indicating a competitive pricing response from Kenvue that could pressure US market share for peers like Church & Dwight and L'Oreal.
근거
“Globally, we are activating our five extraordinary powers, driving stronger consumption performance for the company in Q1 relative to Q4. In fact, consumption for the quarter outpaced organic sales growth across each of our three segments.”
외부 신호
공급망 알파 · 4발표 이후 수익률
Kenvue's gross tariff impact is ~$150M, with ~two-thirds coming from China (at a 145% rate), and the largest import flow being finished goods from Canada (netting to <10% impact after MCA exemptions).
근거
“The biggest importer is Canada, Canada into the US, and most of that is finished goods... It's about two-thirds of the analyzed impact at the current rate of 145%. To give a little more color, two-thirds is finished products, about one-thi…”
April US retail orders tightened, which combined with a delayed allergy/sun season, may shift volumes into later quarters.
Consumption outpaced organic sales growth across all segments in Q1, driven by US price/trade investment, indicating Kenvue is gaining share and household penetration in the US despite retailer destocking.
Tylenol gained share for the 11th straight quarter and was the only brand in its category gaining value and volume share, while Zyrtec grew both value and volume share.
근거
“we capitalize on the seasonal spike in the U.S. and strengthen Tylenol's number one position, gaining share for the 11th straight quarter and widening the gap further with competition. And once again, Tylenol was the only brand in the cate…”
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 8개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.